Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback